Who are Matching Placebo to Sita/Met FDC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): exenatide and sitagliptin, Incretin-based therapy, MET + Vildagliptin Group, SGLT2i+Metformin+Cofrogliptin, Anagliptin BID Treatment, Saxagliptin + Metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/matching-placebo-to-sita-met-fdc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Matching Placebo to Sita/Met FDC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Matching Placebo to Sita/Met FDC (Matching Placebo to Sita/Met FDC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor and biguanide combination. Area: Diabetes.

phase 3 DPP-4 inhibitor and biguanide combination DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Matching Placebo to Sita/Met FDC (Matching Placebo to Sita/Met FDC) — Merck Sharp & Dohme LLC. Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Matching Placebo to Sita/Met FDC TARGET	Matching Placebo to Sita/Met FDC	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor and biguanide combination	DPP-4
exenatide and sitagliptin	exenatide and sitagliptin	AstraZeneca	marketed	GLP-1 receptor agonist and DPP-4 inhibitor combination	GLP-1 receptor (exenatide); DPP-4 (sitagliptin)
Incretin-based therapy	Incretin-based therapy	Nagaoka Red Cross Hospital	marketed	Incretin mimetic or DPP-4 inhibitor	GLP-1 receptor or DPP-4
MET + Vildagliptin Group	MET + Vildagliptin Group	Hospital de Clinicas de Porto Alegre	marketed	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
SGLT2i+Metformin+Cofrogliptin	SGLT2i+Metformin+Cofrogliptin	Huazhong University of Science and Technology	marketed	SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination)	SGLT2, mitochondrial complex I, DPP-4
Anagliptin BID Treatment	Anagliptin BID Treatment	JW Pharmaceutical	marketed	DPP-4 inhibitor	Dipeptidyl peptidase-4 (DPP-4)
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor and biguanide combination class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Matching Placebo to Sita/Met FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/matching-placebo-to-sita-met-fdc. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab